Douglas L. Forrester

Douglas L. Forrester

Auto-generated profile, based on publicly available information

Douglas L. Forrester

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
GMGraeme Mattison
Graeme Mattison
OCOliver J Canfell
Oliver J Canfell
DFDoug Forrester
Doug Forrester
CDChelsea Dobbins
Chelsea Dobbins
DSDaniel Smith
Daniel Smith
CSClair Sullivan
Clair Sullivan
Background: Chronic diseases contribute to high rates of disability and mortality. Patient engagement in chronic disease self-management is an essential component of chronic disease models of health care. Wearables provide patient-centered health data in real time, which can help inform self-management decision-making. Despite the perceived benefits of wearables in improving chronic disease self-management, their influence on health care outcomes remains poorly understood. Objective: This review aimed to examine the influence of wearables on health care outcomes in individuals with chronic diseases through a systematic review of the literature. Methods: A narrative systematic review was conducted by searching 6 databases for randomized and observational studies published between January 1, 2016, and July 1, 2021, that included the use of a wearable intervention in a chronic disease group to assess its impact on a predefined outcome measure. These outcomes were defined as any influence on the patient or clinician experience, cost-effectiveness, or health care outcomes as a result of the wearable intervention. Data from the included studies were extracted based on 6 key themes, which formed the basis for a narrative qualitative synthesis. All outcomes were mapped against each component of the Quadruple Aim of health care. The guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed in this study. Results: A total of 30 articles were included; studies reported 2446 participants (mean age: range 10.1-74.4 years), and the influence of 14 types of wearables on 18 chronic diseases was presented. The most studied chronic diseases were type 2 diabetes (4/30, 13%), Parkinson disease (3/30, 10%), and chronic lower back pain (3/30, 10%). The results were mixed when assessing the impact on a predefined primary outcome, with 50% (15/30) of studies finding a positive influence on the studied outcome and 50% (15/30) demonstrating a nil effect. There was a positive effect of 3D virtual reality systems on chronic pain in 7% (2/30) of studies that evaluated 2 distinct chronic pain syndromes. Mixed results were observed in influencing exercise capacity; weight; and biomarkers of disease, such as hemoglobin A1c, in diabetes. In total, 155 outcomes were studied. Most (139/155, 89.7%) addressed the health care outcomes component. This included pain (11/155, 7.5%), quality of life (7/155, 4.8%), and physical function (5/155, 3.4%). Approximately 7.7% (12/155) of outcome measures represented the patient experience component, with 1.3% (2/155) addressing the clinician experience and cost. Conclusions: Given their popularity and capability, wearables may play an integral role in chronic disease management. However, further research is required to generate a strong evidence base for safe and effective implementation. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021244562; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=244562

28 May 2015 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
HBHelen L. Barr
Helen L. Barr
NHNigel Halliday
Nigel Halliday
MCMiguel Camara
Miguel Camara
DBDavid A. Barrett
David A. Barrett
PWPaul Williams
Paul Williams
AFAndrew W. Fogarty
Andrew W. Fogarty
Pseudomonas aeruginosaproduces quorum sensing signal molecules that are potential biomarkers for infection.A prospective study of 60 cystic fibrosis patients with chronicP. aeruginosa,who required intravenous antibiotics for pulmonary exacerbations, was undertaken. Clinical measurements and biological samples were obtained at the start and end of the treatment period. Additional data were available for 29 of these patients when they were clinically stable.Cross-sectionally, quorum sensing signal molecules were detectable in the sputum, plasma and urine of 86%, 75% and 83% patients, respectively. They were positively correlated between the three biofluids. Positive correlations were observed for most quorum sensing signal molecules in sputum, plasma and urine, with quantitative measures of pulmonaryP. aeruginosaload at the start of a pulmonary exacerbation. Plasma concentrations of 2-nonyl-4-hydroxy-quinoline (NHQ) were significantly higher at the start of a pulmonary exacerbation compared to clinical stability (p<0.01). Following the administration of systemic antibiotics, plasma 2-heptyl-4-hydroxyquinoline (p=0.02) and NHQ concentrations (p<0.01) decreased significantly.In conclusion, quorum sensing signal molecules are detectable in cystic fibrosis patients with pulmonaryP. aeruginosainfection and are positively correlated with quantitative measures ofP. aeruginosa. NHQ correlates with clinical status and has potential as a novel biomarker forP. aeruginosainfection.

1 July 2019 in Australian Journal of General Practice
Verified
Journal Article
Closed access
PNPyi Naing
Pyi Naing
DFDouglas Forrester
Douglas Forrester
NKNadarajah Kangaharan
Nadarajah Kangaharan
AMAruna Muthumala
Aruna Muthumala
SMSu Mon Myint
Su Mon Myint
DPDavid Playford
David Playford
Heart failure with preserved ejection fraction (HFpEF) is an emerging global health problem of which there is limited awareness. HFpEF has a prognosis similar to that of heart failure with reduced ejection fraction (HFrEF) and accounts for approximately half of all patients with heart failure. The aim of this article is to review HFpEF and its consequences and management, including examples of patients with HFpEF. Patients with HFpEF may present with dyspnoea, fluid retention, lethargy and dizziness, making it difficult to differentiate clinically from HFrEF. The risk factors include increasing age, obesity, hypertension, diabetes, chronic kidney disease and obstructive sleep apnoea. The diagnosis requires good clinical acumen combined with echocardiography and elevated plasma B-type natriuretic peptide concentration. Management of HFpEF, especially in later stages, is difficult as there is no evidence-based therapy to date. Prevention is the best strategy. Early recognition and diagnosis are also very important to tackle this global epidemic.

21 September 2016 in Physiological Reports
Verified
Journal Article
Open access
PDF file
MSMariel Slater
Mariel Slater
ETElizabeth Torr
Elizabeth Torr
THTim Harrison
Tim Harrison
DFDoug Forrester
Doug Forrester
AKAlan Knox
Alan Knox
ISIan Sayers
Ian Sayers
Macrolides including azithromycin (AZM) can improve clinical symptoms in asthma regardless of infection status. The mechanisms underlying these beneficial effects are yet to be elucidated. The aim of this study was to determine the effect of AZM on the airway epithelial barrier both in an in vitro model and in patients with asthma. Primary human bronchial epithelial cells (HBEC) were grown at air liquid interface (ALI) and challenged using lipopolysaccharides from Pseudomonas aeruginosa . AZM was added at various stages and barrier integrity assessed using transepithelial electrical resistance (TEER) and permeability to FITC‐dextran. MMP‐9 levels were measured using ELISA. AZM enhanced barrier integrity (TEER/FITC‐dextran), increased thickness, suppressed mucin production, and MMP‐9 release during the formation of a normal epithelial barrier in vitro. MMP‐9 levels inversely correlated with TEER. AZM also enhanced maintenance of the barrier and facilitated repair post‐LPS challenge. To provide translation of our findings, 10 patients with moderate‐severe asthma were recruited and received 250 mg AZM o.d for 6 weeks. Bronchial biopsies taken pre‐ and post‐AZM treatment did not show evidence of increased epithelial barrier thickness or decreased mucin production. Similarly, bronchial wash samples did not show reduced MMP‐9 levels. Overall, our data show that AZM can significantly improve the development of a normal bronchial epithelial barrier in vitro, mimicking reepithelization postinjury. AZM also suppressed MMP‐9 release which correlated with barrier integrity, suggesting a putative mechanism. However, these effects were not observed in biopsy samples from asthma patients treated with AZM, possibly due to small sample size.

30 November 2018 in Respirology
Verified
Journal Article
Open access
PDF file
VNVidya Navaratnam
Vidya Navaratnam
DFDouglas L. Forrester
Douglas L. Forrester
KEKah Peng Eg
Kah Peng Eg
Anne B. ChangAnne B. Chang
Anne B. Chang
Bronchiectasis is a chronic lung disease associated with structurally abnormal bronchi, clinically manifested by a persistent wet/productive cough, airway infections and recurrent exacerbations. Early identification and treatment of acute exacerbations is an integral part of monitoring and annual review, in both adults and children, to minimize further damage due to infection and inflammation. Common modalities used to monitor disease progression include clinical signs and symptoms, frequency of exacerbations and/or number of hospital admissions, lung function (forced expiratory volume in 1 s (FEV 1 )% predicted), imaging (radiological severity of disease) and sputum microbiology (chronic infection with Pseudomonas aeruginosa ). There is good evidence that these monitoring tools can be used to accurately assess severity of disease and predict prognosis in terms of mortality and future hospitalization. Other tools that are currently used in research settings such as health‐related quality of life (QoL) questionnaires, magnetic resonance imaging and lung clearance index can be burdensome and require additional expertise or resource, which limits their use in clinical practice. Studies have demonstrated that cross‐infection, especially with P. aeruginosa between patients with bronchiectasis is possible but infrequent. This should not limit participation of patients in group activities such as pulmonary rehabilitation, and simple infection control measures should be carried out to limit the risk of cross‐transmission. A multidisciplinary approach to care which includes respiratory physicians, chest physiotherapists, nurse specialists and other allied health professionals are vital in providing holistic care. Patient education and personalized self‐management plans are also important despite limited evidence it improves QoL or frequency of exacerbations.

6 October 2010
Verified
Reference Entry
Closed access
PDF file
MHMatthew N Hurley
Matthew N Hurley
DFDouglas L Forrester
Douglas L Forrester
ASAlan R Smyth
Alan R Smyth